Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 39 | 2025 | 223 | 7.210 |
Why?
|
| Coronary Vessels | 20 | 2025 | 118 | 3.520 |
Why?
|
| Coronary Artery Disease | 18 | 2025 | 310 | 3.210 |
Why?
|
| Drug-Eluting Stents | 15 | 2017 | 62 | 2.420 |
Why?
|
| Neointima | 9 | 2021 | 19 | 1.720 |
Why?
|
| Cerebral Arteries | 2 | 2024 | 40 | 1.510 |
Why?
|
| Angioplasty, Balloon, Coronary | 11 | 2017 | 168 | 1.490 |
Why?
|
| Percutaneous Coronary Intervention | 9 | 2023 | 208 | 1.380 |
Why?
|
| Plaque, Atherosclerotic | 7 | 2023 | 33 | 1.090 |
Why?
|
| Intracranial Aneurysm | 5 | 2024 | 366 | 1.040 |
Why?
|
| Optical Imaging | 3 | 2016 | 71 | 1.000 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2017 | 289 | 0.920 |
Why?
|
| Stents | 11 | 2022 | 491 | 0.850 |
Why?
|
| Microscopy | 2 | 2024 | 91 | 0.850 |
Why?
|
| Sirolimus | 9 | 2017 | 92 | 0.820 |
Why?
|
| Carotid Arteries | 2 | 2020 | 61 | 0.780 |
Why?
|
| Algorithms | 6 | 2014 | 999 | 0.780 |
Why?
|
| Coronary Angiography | 11 | 2023 | 201 | 0.770 |
Why?
|
| Angiography, Digital Subtraction | 3 | 2024 | 134 | 0.750 |
Why?
|
| Predictive Value of Tests | 12 | 2025 | 1082 | 0.720 |
Why?
|
| Coronary Restenosis | 6 | 2017 | 20 | 0.710 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2014 | 178 | 0.680 |
Why?
|
| Vertebral Artery | 1 | 2020 | 28 | 0.670 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2020 | 33 | 0.670 |
Why?
|
| Basilar Artery | 1 | 2020 | 32 | 0.660 |
Why?
|
| Embolization, Therapeutic | 2 | 2020 | 318 | 0.650 |
Why?
|
| Coronary Stenosis | 4 | 2016 | 39 | 0.630 |
Why?
|
| Rabbits | 8 | 2024 | 332 | 0.630 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2016 | 41 | 0.570 |
Why?
|
| Angina, Unstable | 2 | 2014 | 58 | 0.530 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 67 | 0.510 |
Why?
|
| Treatment Outcome | 19 | 2024 | 5659 | 0.500 |
Why?
|
| Everolimus | 7 | 2017 | 22 | 0.470 |
Why?
|
| Automation | 5 | 2016 | 54 | 0.440 |
Why?
|
| Molecular Imaging | 1 | 2014 | 48 | 0.430 |
Why?
|
| Cardiovascular Agents | 5 | 2017 | 104 | 0.430 |
Why?
|
| Thrombosis | 3 | 2020 | 199 | 0.390 |
Why?
|
| Subtraction Technique | 1 | 2012 | 23 | 0.380 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 659 | 0.350 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 1650 | 0.320 |
Why?
|
| Humans | 33 | 2025 | 63309 | 0.310 |
Why?
|
| Animals | 14 | 2024 | 20609 | 0.290 |
Why?
|
| Endovascular Procedures | 3 | 2024 | 648 | 0.290 |
Why?
|
| Contrast Media | 3 | 2025 | 425 | 0.270 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2017 | 19 | 0.260 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 2179 | 0.260 |
Why?
|
| Atherosclerosis | 2 | 2021 | 153 | 0.260 |
Why?
|
| Male | 20 | 2025 | 29831 | 0.250 |
Why?
|
| Cardiac Catheterization | 3 | 2017 | 281 | 0.250 |
Why?
|
| Indocyanine Green | 2 | 2016 | 10 | 0.240 |
Why?
|
| Swine | 3 | 2021 | 374 | 0.240 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 377 | 0.230 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2017 | 90 | 0.230 |
Why?
|
| Prosthesis Design | 6 | 2016 | 227 | 0.230 |
Why?
|
| Miniaturization | 1 | 2024 | 10 | 0.220 |
Why?
|
| Wound Healing | 3 | 2014 | 189 | 0.220 |
Why?
|
| Fluorescent Dyes | 2 | 2016 | 198 | 0.210 |
Why?
|
| Coronary Disease | 2 | 2015 | 246 | 0.210 |
Why?
|
| Middle Aged | 14 | 2025 | 17559 | 0.210 |
Why?
|
| Iliac Artery | 2 | 2014 | 49 | 0.210 |
Why?
|
| Ultrasonography, Interventional | 4 | 2016 | 107 | 0.200 |
Why?
|
| Prosthesis Failure | 4 | 2017 | 74 | 0.190 |
Why?
|
| Paclitaxel | 2 | 2014 | 99 | 0.190 |
Why?
|
| Aspirin | 2 | 2020 | 171 | 0.190 |
Why?
|
| Subarachnoid Space | 1 | 2022 | 10 | 0.190 |
Why?
|
| Arteritis | 1 | 2021 | 4 | 0.180 |
Why?
|
| PPAR alpha | 1 | 2021 | 34 | 0.180 |
Why?
|
| Absorbable Implants | 2 | 2017 | 9 | 0.170 |
Why?
|
| Heart | 1 | 2023 | 281 | 0.170 |
Why?
|
| Pancreatic Elastase | 1 | 2020 | 32 | 0.170 |
Why?
|
| Aged | 13 | 2025 | 14398 | 0.170 |
Why?
|
| Time Factors | 6 | 2025 | 3763 | 0.170 |
Why?
|
| Hyperplasia | 3 | 2021 | 88 | 0.170 |
Why?
|
| Angiography | 1 | 2020 | 152 | 0.160 |
Why?
|
| Cadaver | 1 | 2020 | 128 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2025 | 568 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 181 | 0.150 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 226 | 0.140 |
Why?
|
| Vascular Patency | 2 | 2015 | 139 | 0.130 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 21 | 0.130 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2020 | 46 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 71 | 0.120 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 66 | 0.120 |
Why?
|
| Pattern Recognition, Automated | 2 | 2014 | 53 | 0.120 |
Why?
|
| Fibrosis | 1 | 2016 | 160 | 0.120 |
Why?
|
| Female | 14 | 2025 | 32803 | 0.120 |
Why?
|
| Observer Variation | 2 | 2015 | 213 | 0.110 |
Why?
|
| Lipids | 1 | 2016 | 314 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 2457 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2023 | 3284 | 0.110 |
Why?
|
| Vascular System Injuries | 1 | 2014 | 21 | 0.110 |
Why?
|
| Retreatment | 1 | 2013 | 47 | 0.100 |
Why?
|
| Coronary Circulation | 1 | 2012 | 52 | 0.100 |
Why?
|
| Models, Animal | 1 | 2013 | 236 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2013 | 201 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 104 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2012 | 76 | 0.100 |
Why?
|
| Medical Records | 1 | 2012 | 137 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 178 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2012 | 191 | 0.080 |
Why?
|
| Dogs | 2 | 2022 | 325 | 0.080 |
Why?
|
| Cerebral Angiography | 2 | 2022 | 290 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1146 | 0.080 |
Why?
|
| Research Design | 1 | 2011 | 573 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1542 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 325 | 0.070 |
Why?
|
| Forecasting | 2 | 2019 | 232 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2013 | 2077 | 0.060 |
Why?
|
| Acute Disease | 2 | 2020 | 672 | 0.060 |
Why?
|
| Inflammation | 2 | 2021 | 1145 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 5452 | 0.050 |
Why?
|
| Intravital Microscopy | 1 | 2022 | 12 | 0.050 |
Why?
|
| Metals | 2 | 2013 | 65 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2021 | 5 | 0.050 |
Why?
|
| Butyrates | 1 | 2021 | 16 | 0.050 |
Why?
|
| Microsurgery | 1 | 2022 | 51 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 129 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2021 | 185 | 0.040 |
Why?
|
| Arteries | 1 | 2020 | 81 | 0.040 |
Why?
|
| Adult | 4 | 2017 | 16792 | 0.040 |
Why?
|
| Hyperemia | 1 | 2017 | 13 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 68 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 174 | 0.030 |
Why?
|
| Adenosine | 1 | 2017 | 78 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1170 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2016 | 29 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 156 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 248 | 0.030 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2015 | 18 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 123 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 232 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 323 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 263 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 851 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 54 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 973 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 608 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 334 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 112 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 279 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2012 | 15 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 2012 | 21 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 73 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 90 | 0.020 |
Why?
|
| Belgium | 1 | 2011 | 6 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1747 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 349 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 462 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 482 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 663 | 0.020 |
Why?
|